The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF), if the drug is administered to certain patients with kidney disease. Three of the GBCAs - Magnevist, Omniscan, and Optimark - will be described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease... 
More...
More...